Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
KYTX
KYTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYTX News
Kyverna Presents New Therapies at Neurology Annual Meeting
5d ago
Newsfilter
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
Dec 26 2025
Benzinga
Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
Dec 20 2025
NASDAQ.COM
Crude Oil Increases by More Than 1%; General Mills Reports Earnings Exceeding Expectations
Dec 17 2025
Benzinga
Kyverna Therapeutics Prices 13.33M Shares at $7.50, Raising Approximately $100M
Dec 17 2025
Newsfilter
Dow Rises by 150 Points as Jabil Reports Positive Earnings
Dec 17 2025
Benzinga
Aditxt Shares Surge Approximately 63%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 17 2025
Benzinga
Lightwave Logic, Kyverna Therapeutics, and Other Major Stocks Decline in Tuesday's Pre-Market Trading
Dec 16 2025
Benzinga
Kyverna Therapeutics Launches $100 Million Underwritten Public Offering to Fund Cell Therapy Development
Dec 15 2025
Globenewswire
Kyverna Therapeutics Launches $100 Million Public Offering with $15 Million Underwriter Option
Dec 15 2025
Newsfilter
Kyverna Stock Soars 27% Following Encouraging Topline Results from CAR-T Autoimmune Research
Dec 15 2025
NASDAQ.COM
Crude Oil Declines by More Than 1%; US Homebuilder Confidence Rises Slightly in December
Dec 15 2025
Benzinga
Kyverna Therapeutics Plans $100M Public Offering
Dec 15 2025
SeekingAlpha
Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday
Dec 15 2025
Benzinga
Kyverna's Miv-cel Demonstrates Promising Outcomes in Phase 2 KYSA-8 Trial for Stiff Person Syndrome - Update
Dec 15 2025
NASDAQ.COM
Show More News
